Indivior Pharmaceuticals (INDV) Receivables - Net (2021 - 2026)

Indivior Pharmaceuticals' Receivables - Net history runs 6 years deep, the most recent figure standing at $273.0 million for Q1 2026.

• On a quarterly basis, Receivables - Net rose 12.35% year-over-year to $273.0 million in Q1 2026; TTM through Mar 2026 was $273.0 million, a 12.35% increase from a year earlier, with the FY2025 full-year figure at $253.0 million, changed 0.39% from the prior year.
• Receivables - Net climbed to $273.0 million in Q1 2026 per INDV's latest filing, from $253.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $273.0 million in Q1 2026 and bottomed at $220.0 million in Q4 2022.
• The 5-year median for Receivables - Net is $253.5 million (2023), against an average of $249.5 million.
• Across the five-year window, Receivables - Net gained 15.45% in 2023 and slipped 0.39% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $220.0 million in 2022, then climbed by 15.45% to $254.0 million in 2023, then changed by 0.0% to $254.0 million in 2024, then dropped by 0.39% to $253.0 million in 2025, then gained by 7.91% to $273.0 million in 2026.
• Per Business Quant, the three latest INDV Receivables - Net figures stand at $273.0 million (Q1 2026), $253.0 million (Q4 2025), and $259.0 million (Q3 2025).